Beverly Teicher named editor-in-chief of AACR’s Molecular Cancer Therapeutics

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Beverly Teicher was named editor-in-chief of Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research. She officially began her term as editor-in-chief of Molecular Cancer Therapeutics on Jan. 1.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

Login